Spots Global Cancer Trial Database for Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Official Title: A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome

Study ID: NCT04810611

Conditions

Myelodysplastic Syndromes

Interventions

MBG453

NIS793

canakinumab

Study Description

Brief Summary: The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.

Detailed Description: This was a phase Ib, multi center, open-label, platform study with multiple treatment arms. The design of this study was adaptive to allow discontinuation of poorly tolerated or ineffective treatments and to facilitate the introduction of new candidate single agents or combinations. Study design included a dose escalation/confirmation part and a dose expansion. The planned initial single agent and combination treatment arms were the following: * Arm 1: MBG453 single agent * Arm 2: NIS793 single agent * Arm 3: canakinumab single agent * Arm 4: MBG453 + NIS793 combination * Arm 5: MBG453 + canakinumab combination Patients were treated in the dose confirmation/escalation part of the study in Arms 1, 2, 3 and 5. No patients were treated in Arm 4. The study did not progress into the expansion phase.